Vudalimab is a monoclonal antibody commercialized by Xencor, with a leading Phase II program in Cervical Cancer. According to Globaldata, it is involved in 9 clinical trials, of which 1 was completed, 6 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Vudalimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vudalimab is expected to reach an annual total of $184 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vudalimab Overview
XmAb-717 is under development for the treatment of cervical cancer, squamous cell carcinoma of the anus, melanoma, triple-negative breast cancer, high-grade neuroendocrine carcinoma, squamous cell carcinoma of the penus, hepatocellular carcinoma, urothelial cell carcinoma, renal cell carcinoma, colorectal cancer, endometrial cancer, non-small cell lung carcinoma, prostate cancer, mesothelioma, gastroesophageal junction carcinomas, gastric cancer, small cell carcinoma of the lung, head and neck cancer squamous cell carcinoma, nasopharyngeal cancer, cholangiocarcinoma, gall bladder cancer, basal cell carcinoma, ovarian cancer, fallopian tube cancer, peritoneal cancer, thymic carcinoma, vulvar cancer, salivary gland cancer, thymoma, Hodgkin Lymphoma, anaplastic thyroid cancer, spindle cell squamous cell carcinoma, HER2 negative breast cancer and non-small cell lung cancer . It is administered through intravenous route. The drug candidate is a bi-specific monoclonal antibody that acts by targeting programmed cell death protein 1(PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It is developed based on XmAb bi-specific/ Xtend Fc domains antibody engineering technology. It was under development for the treatment of anal cancer.
See Also:
Xencor Overview
Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Its other pipeline includes XmAb306/RO7310729, XmAb968 and XmAb662 (IL12-Fc), among others. Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor is headquartered in Monrovia, California, the US.
The company reported revenues of (US Dollars) US$164.6 million for the fiscal year ended December 2022 (FY2022), a decrease of 40.2% over FY2021. The operating loss of the company was US$82.6 million in FY2022, compared to an operating profit of US$43 million in FY2021. The net loss of the company was US$55.2 million in FY2022, compared to a net profit of US$82.6 million in FY2021.
The company reported revenues of US$59.2 million for the third quarter ended September 2023, an increase of 30% over the previous quarter.
For a complete picture of Vudalimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.